European experience of infliximab biosimilars for the treatment of inflammatory bowel disease

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)119-121
Number of pages3
JournalGastroenterology and Hepatology
Volume12
Issue number2
Publication statusPublished - Feb 1 2016

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Infliximab

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

European experience of infliximab biosimilars for the treatment of inflammatory bowel disease. / Lakatos, P.

In: Gastroenterology and Hepatology, Vol. 12, No. 2, 01.02.2016, p. 119-121.

Research output: Contribution to journalArticle

@article{9bce93f2f49c4166abfddcdeefb1bd62,
title = "European experience of infliximab biosimilars for the treatment of inflammatory bowel disease",
author = "P. Lakatos",
year = "2016",
month = "2",
day = "1",
language = "English",
volume = "12",
pages = "119--121",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "2",

}

TY - JOUR

T1 - European experience of infliximab biosimilars for the treatment of inflammatory bowel disease

AU - Lakatos, P.

PY - 2016/2/1

Y1 - 2016/2/1

UR - http://www.scopus.com/inward/record.url?scp=84958959732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958959732&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84958959732

VL - 12

SP - 119

EP - 121

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 2

ER -